Omeros Future Growth
Future criteria checks 2/6
Omeros is forecast to grow earnings and revenue by 38.2% and 65.2% per annum respectively while EPS is expected to grow by 42.5% per annum.
Key information
38.2%
Earnings growth rate
42.5%
EPS growth rate
| Pharmaceuticals earnings growth | 19.0% |
| Revenue growth rate | 65.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 09 Aug 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 26 | -134 | N/A | N/A | 2 |
| 12/31/2025 | 8 | -156 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -176 | N/A | N/A | 2 |
| 6/30/2024 | N/A | -200 | -156 | -155 | N/A |
| 3/31/2024 | N/A | -179 | -142 | -142 | N/A |
| 12/31/2023 | N/A | -175 | 74 | 75 | N/A |
| 9/30/2023 | N/A | -182 | 84 | 84 | N/A |
| 6/30/2023 | N/A | -185 | 90 | 90 | N/A |
| 3/31/2023 | N/A | -182 | 103 | 103 | N/A |
| 12/31/2022 | N/A | -182 | -87 | -86 | N/A |
| 9/30/2022 | N/A | -183 | -79 | -79 | N/A |
| 6/30/2022 | N/A | -173 | -77 | -77 | N/A |
| 3/31/2022 | N/A | -181 | -85 | -85 | N/A |
| 12/31/2021 | N/A | -192 | -110 | -110 | N/A |
| 9/30/2021 | -63 | -217 | -110 | -110 | N/A |
| 6/30/2021 | -37 | -211 | -121 | -121 | N/A |
| 3/31/2021 | -24 | -194 | -131 | -131 | N/A |
| 12/31/2020 | N/A | -173 | -100 | -100 | N/A |
| 9/30/2020 | 97 | -130 | -105 | -105 | N/A |
| 6/30/2020 | 100 | -108 | -78 | -77 | N/A |
| 3/31/2020 | 114 | -89 | -56 | -56 | N/A |
| 12/31/2019 | N/A | -147 | -60 | -60 | N/A |
| 9/30/2019 | 100 | -79 | -62 | -62 | N/A |
| 6/30/2019 | 75 | -102 | -92 | -91 | N/A |
| 3/31/2019 | 50 | -121 | -106 | -105 | N/A |
| 12/31/2018 | 30 | -127 | -104 | -104 | N/A |
| 9/30/2018 | 22 | -120 | -84 | -83 | N/A |
| 6/30/2018 | 39 | -88 | -58 | -58 | N/A |
| 3/31/2018 | 54 | -68 | N/A | -35 | N/A |
| 12/31/2017 | 65 | -53 | N/A | -36 | N/A |
| 9/30/2017 | 64 | -57 | N/A | -43 | N/A |
| 6/30/2017 | 54 | -63 | N/A | -43 | N/A |
| 3/31/2017 | 46 | -61 | N/A | -48 | N/A |
| 12/31/2016 | 42 | -67 | N/A | -52 | N/A |
| 9/30/2016 | 35 | -67 | N/A | -57 | N/A |
| 6/30/2016 | 27 | -73 | N/A | -61 | N/A |
| 3/31/2016 | 21 | -77 | N/A | -64 | N/A |
| 12/31/2015 | 14 | -75 | N/A | -65 | N/A |
| 9/30/2015 | 7 | -76 | N/A | -64 | N/A |
| 6/30/2015 | 4 | -74 | N/A | -66 | N/A |
| 3/31/2015 | 1 | -76 | N/A | -64 | N/A |
| 12/31/2014 | 1 | -74 | N/A | -58 | N/A |
| 9/30/2014 | 1 | -55 | N/A | -43 | N/A |
| 6/30/2014 | 1 | -50 | N/A | -38 | N/A |
| 3/31/2014 | 1 | -46 | N/A | -32 | N/A |
| 12/31/2013 | 2 | -40 | N/A | -30 | N/A |
| 9/30/2013 | 3 | -46 | N/A | -42 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3O8 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 3O8 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 3O8 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 3O8's revenue (65.2% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 3O8's revenue (65.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 3O8's Return on Equity is forecast to be high in 3 years time